Liraglutide And Semaglutide Market Report 2026

Liraglutide And Semaglutide Market Overview

• Liraglutide And Semaglutide market size has reached to $16.94 billion in 2025 • Expected to grow to $28.98 billion in 2030 at a compound annual growth rate (CAGR) of 11.3% • Growth Driver: Rising Diabetes Prevalence Drives Growth in Liraglutide and Semaglutide Markets • Market Trend: Advancements In Anti Diabetic Drug Development • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Liraglutide And Semaglutide Market?

Liraglutide and semaglutide refer to medications categorized as glucagon-like peptide-1 (GLP-1) receptor agonists, prescribed primarily for managing type 2 diabetes mellitus and utilized to improve glycemic control in adults with this condition. They are injectable medications and are typically used when other treatments for diabetes or obesity have not been effective enough. They are often part of a comprehensive treatment plan that includes diet, exercise, and other medications as needed. The main types of liraglutide and semaglutide are pills and liquids. Pills refer to medications formulated in solid form, typically taken orally for treating conditions such as type 2 diabetes mellitus and obesity. The various administrations are parenteral, oral, and used for different applications such as type 2 diabetes mellitus and obesity, and others are provided through many distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Liraglutide And Semaglutide Market Growth Forecast?

The liraglutide and semaglutide market size is expected to see rapid growth in the next few years. It will grow to $28.98 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to expanding obesity treatment indications, growing demand for convenient dosing options, increasing adoption of oral semaglutide, rising focus on comprehensive metabolic care, higher healthcare spending on chronic disease management. Major trends in the forecast period include rising adoption of glp-1 receptor agonists for diabetes care, growing use of glp-1 therapies in obesity management, increasing preference for once-weekly injectable treatments, expansion of oral glp-1 formulations, rising long-term use for glycemic and weight control.

Global Liraglutide And Semaglutide Market Segmentation

1) By Type: Pills, Liquid 2) By Administration: Parenteral, Oral 3) By Application: Type 2 Diabetes Mellitus, Obesity, Other Applications 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Pills: Oral Tablets (Liraglutide, Semaglutide), Extended-Release Oral Formulations 2) By Liquid: Injectable Solutions (Liraglutide, Semaglutide), Pre-Filled Syringes, Vials For Injection

What Is The Driver Of The Liraglutide And Semaglutide Market?

The rising number of diabetic patients is expected to propel the growth of the liraglutide and semaglutide markets going forward. Diabetes is a chronic condition characterized by elevated blood sugar levels due to insulin resistance and insufficient insulin production in the body. The rising number of diabetic patients is due to sedentary lifestyles, poor dietary habits, and genetic predispositions. Liraglutide and semaglutide are essential in treating diabetic patients by offering effective management of blood glucose levels and reducing the risk of complications associated with diabetes. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore, the rising number of diabetic patients drives the liraglutide and semaglutide markets.

Key Players In The Global Liraglutide And Semaglutide Market

Major companies operating in the liraglutide and semaglutide market are Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Sanofi S.A., Novartis AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Biocon Ltd., Glenmark Pharmaceuticals Limited, Lupin Limited, Cipla Limited, Aurobindo Pharma Limited, Zydus Lifesciences Limited, Hikma Pharmaceuticals Plc, Viatris Inc., Amneal Pharmaceuticals Inc., Torrent Pharmaceuticals Limited, Intas Pharmaceuticals Limited

Global Liraglutide And Semaglutide Market Trends and Insights

Major companies operating in the liraglutide and semaglutide markets are developing anti-diabetic biosimilar drugs to enhance glucose control and reduce cardiovascular risks in diabetic patients. Anti-diabetic biosimilars are cost-effective, near-identical copies of original diabetes biologics intended to deliver the same health benefits as the original drugs. For instance, in January 2024, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, launched a biosimilar of the popular anti-diabetic drug, Liraglutide, for the first time in India. It is a biosimilar of Liraglutide, an anti-diabetic drug to improve glycemic control among adults with type 2 diabetes mellitus. This launch reduces daily therapy costs, significantly expanding access for more patients nationwide. Priced at approximately INR 100 for a standard 1.2 mg dose per day, this substantially reduces therapy costs by about 70% and requires a prescription for purchase.

What Are Latest Mergers And Acquisitions In The Liraglutide And Semaglutide Market?

In October 2023, Biocon Limited, an India-based biopharmaceutical company developing biosimilar versions of diabetes drugs liraglutide (Victoza) and semaglutide (Ozempic), partnered with Juno Pharmaceuticals. This partnership aims to bring Liraglutide, a complex drug-device combination for treating Type 2 diabetes and obesity, to market, ensuring regulatory approval, manufacturing, and supply, enhancing healthcare access and affordability through innovative treatments. Juno Pharmaceuticals is a Canada-based pharmaceutical company that produces high-value generic medications, complex formulations, biosimilars, and other medicines.

Regional Outlook

North America was the largest region in the liraglutide and semaglutide market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Liraglutide And Semaglutide Market?

The liraglutide and semaglutide markets consist of sales of medicines such as Victoza, saxenda, ozempic, and rybelsus. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Liraglutide And Semaglutide Market Report 2026?

The liraglutide and semaglutide market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the liraglutide and semaglutide industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.